[74] recently conducted a multicentre, randomised, controlled, phase 2 trial in China to assess the efficacy of adjuvant sintilimab, a programmed cell death protein 1 inhibitor, in HCC patients with MVI. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.